Ultragenyx Pharmaceutical Inc.
NASDAQUltragenyx Pharmaceutical heads into the post-earnings period with a notable divergence on the table: short sellers are retreating at pace, while analysts who remain bullish are quietly marking down their price expectations. The most striking shift in recent weeks has been the rapid unwind of short positioning. Short interest in RARE has fallen sharply — from around 16.5 million…
Snapshot as of 6 Aug 2026
Ultragenyx Pharmaceutical heads into the post-earnings period with a notable divergence on the table: short sellers are retreating at pace, while analysts who remain bullish are quietly marking down their price…
Ultragenyx Pharmaceutical heads into the back half of June with a sharp disconnect between its 9% weekly rally and an options market suddenly pricing in the most defensive posture it has struck in nearly a year. The…
Ultragenyx Pharmaceutical heads into the post-earnings week with short sellers adding positions and analysts pulling in opposite directions — a split that reflects the market's unresolved read on whether the Q1 revenue…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RARE — free to start on ORTEX.
Sign up for free →Open RARE on ORTEX